This preprint is under consideration at SN Comprehensive Clinical Medicine. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Case Report
Massimo Napolitano
Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli
Corresponding Author
ORCiD: https://orcid.org/0000-0003-1853-2737
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Anti Yo antibodies (AYA) are the antibodies most frequently identified with Paraneoplastic Cerebellar Degeneration (PCD). They are detected above all in PCD associated with breast and gynecologic malignancies. Here, we report a third case of PCD with cerebellar contrast enhancement findings at MRI. In fact, AYA cross anti cerebellar cortex immune reaction leads mainly to hyperintensity signals in T2-weighted-MRI sequences, followed by cerebellar atrophy. As such, meningeal contrast enhancement could lead to a diagnostic pitfall as it can be considered a carcinomatosis - above all in serum antibody negative cases as well as when a metastatic tumour is found. Our patient had no tumoral cells in the cerebrospinal fluid and her neurological syndrome remained stable after immunoglobulin treatment. AYA serum finding was diriment for PCD diagnosis.
Keywords
Paraneoplastic, Degeneration, Carcinomatosis
Figure 1
Figure 2
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 04 Jun, 2021
No community comments so far
Reviews received
Received 27 May, 2021
First submitted
On 13 Apr, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Neurology
Learn more about our company.
This preprint is under consideration at SN Comprehensive Clinical Medicine. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Case Report
Massimo Napolitano
Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli
Corresponding Author
ORCiD: https://orcid.org/0000-0003-1853-2737
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 04 Jun, 2021
No community comments so far
Reviews received
Received 27 May, 2021
First submitted
On 13 Apr, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Neurology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Anti Yo antibodies (AYA) are the antibodies most frequently identified with Paraneoplastic Cerebellar Degeneration (PCD). They are detected above all in PCD associated with breast and gynecologic malignancies. Here, we report a third case of PCD with cerebellar contrast enhancement findings at MRI. In fact, AYA cross anti cerebellar cortex immune reaction leads mainly to hyperintensity signals in T2-weighted-MRI sequences, followed by cerebellar atrophy. As such, meningeal contrast enhancement could lead to a diagnostic pitfall as it can be considered a carcinomatosis - above all in serum antibody negative cases as well as when a metastatic tumour is found. Our patient had no tumoral cells in the cerebrospinal fluid and her neurological syndrome remained stable after immunoglobulin treatment. AYA serum finding was diriment for PCD diagnosis.
Figure 1
Figure 2
Loading...